

Resource Summary Report

Generated by [dkNET](#) on Sep 14, 2026

ACHN

RRID:CVCL_1067

Type: Cell Line

Proper Citation

RRID:CVCL_1067

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1067

Proper Citation: RRID:CVCL_1067

Description: Cell line ACHN is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Papillary renal cell carcinoma

Defining Citation: [PMID:2041050](#), [PMID:7591954](#), [PMID:8620516](#), [PMID:9331090](#), [PMID:10074909](#), [PMID:10700174](#), [PMID:10929426](#), [PMID:11146448](#), [PMID:11414198](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:17409424](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22949125](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24477694](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:27993170](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ACHN

Cross References: BTO:BTO_0003846, CLO:CLO_0001654, EFO:EFO_0002108, CLDB:cl236, CLDB:cl237, CLDB:cl4951, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1611, BioSample:SAMN01821536, BioSample:SAMN03473205, BioSample:SAMN10988309, cancercellines:CVCL_1067, CCRID:1101HUM-PUMC000334, CCRID:3101HUMSCSP5063, CCRID:3101HUMTCHu199, CCRID:4201HUM-CCTCC00102, CCTCC:GDC0102, Cell_Model_Passport:SIDM00123, ChEMBL-Cells:ChEMBL3307633, ChEMBL-Targets:ChEMBL614519, CLS:300117, Cosmic:687939, Cosmic:849382, Cosmic:875873, Cosmic:877456, Cosmic:897462, Cosmic:905950, Cosmic:974302, Cosmic:979708, Cosmic:982275, Cosmic:1044260, Cosmic:1092592, Cosmic:1152534, Cosmic:1175850, Cosmic:1305374, Cosmic:1312362, Cosmic:1436045, Cosmic:1998434, Cosmic:2520631, Cosmic-CLP:905950, DepMap:ACH-000046, ECACC:88100508, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS569UYK, ENCODE:ENCBS897ZFY, ENCODE:ENCBS972GIY, GDSC:905950, GEO:GSM2093, GEO:GSM50228, GEO:GSM50292, GEO:GSM743482, GEO:GSM750837, GEO:GSM799373, GEO:GSM799436, GEO:GSM846286, GEO:GSM886863, GEO:GSM887928, GEO:GSM1153446, GEO:GSM1181298, GEO:GSM1181324, GEO:GSM1669593, GEO:GSM2124661, IARC_TP53:21039, IBRC:C10105, ICLC:HTL99007, IGRhCellID:ACHN, IZSLER:BS TCL 68, KCB:KCB 200611YJ, KCLB:21611, LiGeA:CCLE_085, LINCS_LDP:LCL-1756, Lonza:1467, NCBI_Iran:C206, NCI-DTP:ACHN, PharmacDB:ACHN_54_2019, PRIDE:PXD001962, PRIDE:PXD003105, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1067, PubChem_Cell_line:CVCL_1067, RCB:RCB1962, SKY/M-FISH/CGH:2789, TKG:TKG 0578, Ubigen:YC-C087, Wikidata:Q54608371

ID: CVCL_1067

Record Creation Time: 20220427T215127+0000

Record Last Update: 20260913T011932+0000

Ratings and Alerts

No rating or validation information has been found for ACHN.

Warning: Discontinued: TKG; TKG 0578

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: RCB; RCB1962

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1057 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Koh J, et al. (2026) ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. *Cancer research*, 86(7), 1676.

Zhu X, et al. (2026) KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability. *iScience*, 29(4), 115198.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. *Cell reports. Medicine*, 7(3), 102644.

Hatayama T, et al. (2026) Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma. *Urologic oncology*, 44(8), 108.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. *iScience*, 29(7), 116386.

Cesana B, et al. (2026) Using 3D Invasion properties of RCC Cell Lines In Vitro to predict their Metastatic Potential In Vivo. *Cell death discovery*, 12(1).

Li YR, et al. (2026) Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma. *STAR protocols*, 7(1), 104340.

Liao C, et al. (2026) Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression. *Cell chemical biology*, 33(4), 461.

Yang T, et al. (2026) Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(42), e20237.

Luo J, et al. (2026) Targeting the ATX-LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e76352.

Lyons H, et al. (2025) RNA polymerase II partitioning is a shared feature of diverse oncofusion condensates. *Cell*, 188(14), 3843.

Cerqua M, et al. (2025) The integrated stress response drives MET oncogene overexpression in cancers. *The EMBO journal*, 44(4), 1107.

van Ooijen H, et al. (2025) A thermoplastic chip for 2D and 3D correlative assays combining screening and high-resolution imaging of immune cell responses. *Cell reports methods*, 5(1), 100965.

Qu Y, et al. (2025) Proteogenomic Analysis Identifies Clinically Relevant Subgroups of Collecting Duct Carcinoma. *Research (Washington, D.C.)*, 8, 0859.

Han P, et al. (2025) Extrachromosomal circular miRNA-gene amplifications contribute to the renal cancer phenotype. *Cell reports*, 44(12), 116660.

Zhang Q, et al. (2025) The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi. *Developmental cell*.

Lee JS, et al. (2025) An ultraconserved snoRNA-like element in long noncoding RNA CRNDE promotes ribosome biogenesis and cell proliferation. *Molecular cell*, 85(8), 1543.

Wang K, et al. (2025) Fibrogenesis-driven tumor progression in clear cell renal cell carcinoma: prognostic, therapeutic implications and the dual role of neuropilin-1. *Cancer cell international*, 25(1), 179.

Schiele P, et al. (2025) CD8⁺ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. *Science advances*, 11(21), eadr9331.

Hase N, et al. (2025) APOBEC3C-mediated NF- κ B activation enhances clear cell renal cell carcinoma progression. *Molecular oncology*, 19(1), 114.